Y Intercept Hong Kong Ltd Sells 129,280 Shares of Compass Pathways PLC Sponsored ADR $CMPS

Y Intercept Hong Kong Ltd lowered its holdings in Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) by 74.2% during the 1st quarter, HoldingsChannel.com reports. The fund owned 44,978 shares of the company’s stock after selling 129,280 shares during the quarter. Y Intercept Hong Kong Ltd’s holdings in Compass Pathways were worth $249,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of the business. Persistent Asset Partners Ltd purchased a new position in shares of Compass Pathways during the fourth quarter worth about $38,000. Caitong International Asset Management Co. Ltd purchased a new stake in Compass Pathways in the fourth quarter valued at approximately $47,000. Advisory Services Network LLC purchased a new stake in Compass Pathways in the third quarter valued at approximately $41,000. North Star Investment Management Corp. lifted its position in Compass Pathways by 1,354.0% during the first quarter. North Star Investment Management Corp. now owns 7,517 shares of the company’s stock valued at $42,000 after purchasing an additional 7,000 shares during the last quarter. Finally, MML Investors Services LLC bought a new stake in Compass Pathways during the fourth quarter valued at approximately $69,000. Institutional investors own 46.19% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have commented on CMPS shares. Stifel Nicolaus boosted their price target on shares of Compass Pathways from $14.00 to $21.00 and gave the stock a “buy” rating in a research note on Tuesday, July 7th. Compass Point set a $25.00 price objective on shares of Compass Pathways in a report on Tuesday, July 7th. HC Wainwright reiterated a “buy” rating and issued a $70.00 target price on shares of Compass Pathways in a research report on Wednesday, July 8th. Royal Bank Of Canada increased their target price on Compass Pathways from $21.00 to $22.00 and gave the company an “outperform” rating in a research note on Thursday, May 14th. Finally, Raymond James Financial restated a “buy” rating on shares of Compass Pathways in a research report on Friday, May 22nd. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Compass Pathways has a consensus rating of “Moderate Buy” and an average target price of $24.15.

Compass Pathways Stock Down 0.6%

CMPS opened at $13.31 on Thursday. The company has a market cap of $1.80 billion, a P/E ratio of -4.23 and a beta of 2.47. The business’s 50-day moving average price is $12.24 and its 200-day moving average price is $8.77. The company has a current ratio of 3.32, a quick ratio of 3.32 and a debt-to-equity ratio of 0.15. Compass Pathways PLC Sponsored ADR has a 12 month low of $3.50 and a 12 month high of $15.40.

Compass Pathways (NASDAQ:CMPS) last released its earnings results on Wednesday, May 13th. The company reported ($0.30) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.15. On average, equities analysts expect that Compass Pathways PLC Sponsored ADR will post -1.24 EPS for the current year.

Compass Pathways Company Profile

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.